| Identification | Back Directory | [Name]
Imidazo[1,5-a]pyrazine, 5,6,7,8-tetrahydro- (9CI) | [CAS]
297172-19-1 | [Synonyms]
4H,5H,6H,7H-iMidazo[1,5-a]pyrazine
5H,6H,7H,8H-imidazo[1,5-a]pyrazine
5,6,7,8-tetrahydroimidazo[1,5-A]pyrazin
IMidazo[1,5-a]pyrazine, 5,6,7,8-tetrahydro-
1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazine
5,6,7,8-Tetrahydroimidazolo[1,5-a]piperazine
Imidazo[1,5-a]pyrazine, 5,6,7,8-tetrahydro- (9CI)
5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine(SALTDATA: 2HCl) | [Molecular Formula]
C6H9N3 | [MDL Number]
MFCD09263955 | [MOL File]
297172-19-1.mol | [Molecular Weight]
123.156 |
| Chemical Properties | Back Directory | [Boiling point ]
340.0±30.0 °C(Predicted) | [density ]
1.33±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C(protect from light) | [form ]
solid | [pka]
8.26±0.20(Predicted) | [color ]
Cream | [CAS DataBase Reference]
297172-19-1 |
| Hazard Information | Back Directory | [Uses]
5,6,7,8-Tetrahydroimidazo[1,5-A]pyrazine can be used as KRAS G12C inhibitors as antitumor agents. | [Synthesis]
GENERAL STEPS: 7-Benzyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine (4.89 g, 22.9 mmol) was dissolved in anhydrous ethanol (200 mL) and 10% palladium carbon catalyst (4.88 g) was added. The reaction mixture was placed under 1 bar hydrogen atmosphere and the reaction was vigorously stirred at room temperature overnight. Upon completion of the reaction, the catalyst was removed by filtration through a diatomaceous earth pad and the filter cake was washed with ethanol. The filtrates were combined, concentrated under reduced pressure and subsequently co-evaporated with dichloromethane to completely remove the residual solvent to afford the target compound 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine as an off-white oil (2.52 g). The product was characterized by 1H NMR (CD3OD): δ 7.42 (s, 1H), 6.77 (s, 1H), 4.07 (s, 2H), 3.99 (t, J = 5.6 Hz, 2H), 3.22 (t, J = 5.6 Hz, 2H), 1.76 (br s, 1H). LC/MS analysis showed m/z 124 [M + H]+, which is consistent with target molecular weight. | [References]
[1] Patent: WO2015/91795, 2015, A1. Location in patent: Paragraph 36 |
|
|